Imaging Young Myeloma (IMAgerie JEune Myélome)

Nantes University Hospital152 enrolled

Overview

Multicenter open-label prospective comparative study of PET-scan and MRI at the time of diagnosis, after 3 cycles of induction therapy (RVD) and at the completion of therapy.

Study Type

INTERVENTIONAL

Allocation

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

152

Conditions

Multiple Myeloma

Interventions

PET scanPROCEDURE

Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy

MRIPROCEDURE

Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * symptomatic de novo multiple myeloma * less than 65 years of age * enrolled in the IFM/DFCI clinical trial Exclusion Criteria: * 66 years of age or more * not eligible for high-dose therapy * Cons-indications to MRI or PET-Scan

Locations (17)

Bordeaux University Hospital

Bordeaux, France

Brest University Hospital "CHU du Morvan"

Brest, France

Hospital "Côte de Nacre"

Outcomes

Primary Outcomes

Number of patients with at least one lesion not detected on the MRI lesions

Time frame: At diagnosis

Secondary Outcomes

Negativity of the exam after 3 cycles of chemotherapy and just before the maintenance treatment

Time frame: 3 months and 7 months

Number of lesions at diagnosis

Time frame: Inclusion (diagnosis)

diffuse disease at diagnosis

Time frame: Diagnosis time (inclusion)

Direct costs of PET and MRI at diagnosis, after the first cycles of chemotherapy and before the maintenance treatment

Time frame: Inclusion, 3 months and 7 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.